DANIMER SCIENTIFIC ALERT: Bragar Eagel & Squire, P.C. is Investigating Danimer Scientific, Inc. on Behalf of Danimer Stockholders and Encourages Investors to Contact the Firm

DANIMER SCIENTIFIC ALERT: Bragar Eagel & Squire, P.C. is Investigating Danimer Scientific, Inc. on Behalf of Danimer Stockholders and Encourages Investors to Contact the Firm

NEW YORK–(BUSINESS WIRE)–
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Danimer Scientific, Inc. (NYSE: DNMR) on behalf of Danimer stockholders. Our investigation concerns whether Danimer has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On March 20, 2021, the Wall Street Journal published an article entitled “Plastic Straws That Quickly Biodegrade in the Ocean, Not Quite, Scientists Say” addressing, among other things, Danimer’s claims that Nodax, a plant-based plastic that Danimer markets, breaks down far more quickly than fossil-fuel plastics. The Wall Street Journal article alleges that according to several experts on biodegradable plastics, “many claims about Nodax are exaggerated and misleading.” While Danimer reportedly asserts its claims are factual, the article cites at least one expert as stating that making broad claims about Nodax’s biodegradability “is not accurate” and is “greenwashing.”

On March 22, 2021, the first trading day following publication of the Wall Street Journal article, Danimer’s stock price fell $6.43 per share, or roughly 13%, to close at $43.55 per share on March 22, 2021.

If you purchased or otherwise acquired Danimer shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Melissa Fortunato, Esq.

Marion Passmore, Esq.

(212) 355-4648

[email protected]

www.bespc.com

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo

CANOO ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Canoo, Inc. and Encourages Investors to Contact the Firm

CANOO ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Canoo, Inc. and Encourages Investors to Contact the Firm

NEW YORK–(BUSINESS WIRE)–
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of investors that purchased Canoo, Inc. (NASDAQ: GOEV) securities between August 18, 2020 and March 29, 2021, inclusive (the “Class Period”). Investors have until June 1, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Click here to participate in the action.

Canoo was formed by a business combination between Hennessy Capital Acquisition Corp. IV (a special purpose acquisition (SPAC) company) and Canoo Holdings Limited in December 2020. The Company is a mobile technology company that develops electric vehicles. The complaint, filed on April 2, 2021, alleges that prior to and after the combination, the Company promoted a business model based on a three-phased approach to generating revenue and growth: (i) an engineering services segment, (ii) the sales of subscriptions to vehicles to consumers, and (iii) the sale of vehicles to other businesses.

On March 29, 2021, the Company revealed that it was radically changing its business model by deemphasizing its engineering services business and by no longer focusing on its subscription-based business.

In response to this news, shares of Canoo fell $2.50 (or $21.2%) from a March 29, 2021 close of $11.80 per share to close at $9.30 per share on March 30, 2021.

The complaint further alleges that defendants misled investors by misrepresenting and/or failing to disclose that: (i) the Company’s engineering services segment was not a viable business, would not provide meaningful revenue in 2021, and would not reduce operational risk; (ii) that the Company would no longer be focused on its subscription-based business model; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you purchased Canoo securities during the Class Period and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Melissa Fortunato, Esq.

Marion Passmore, Esq.

(212) 355-4648

[email protected]

www.bespc.com

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo

IntelliCentrics Examines Why the COVID-19 Vaccination Falls Short of Being a Total Solution

IntelliCentrics Examines Why the COVID-19 Vaccination Falls Short of Being a Total Solution

In a newly published white paper, IntelliCentrics presents why support from the technology sector is essential to achieving herd immunity

DALLAS–(BUSINESS WIRE)–
IntelliCentrics (6819.HK), the innovator of the SEC³URE Ethos, SEC³URE Passport, Link & GO!, BioBytes™ and BioBytes™ Visitor, serving healthcare facilities across North America, the United Kingdom, and China, releases a special white paper entitled “COVID-19 Vaccine – Impact on Healthcare.” At a high level, the paper reviews the impact of the vaccine’s distribution and the need for a new level of trust in healthcare.

“The arrival of the COVID-19 vaccine creates a mixed society, ushering in significant complexity to our return to normalcy. There are those who have been vaccinated, those who want to be vaccinated, those who have credible reasons not to be vaccinated, and those who have no interest in being vaccinated. This dynamic will persist for years to come,” said Mike Sheehan, CEO of IntelliCentrics. “The core thesis of the paper posits how the COVID-19 vaccine’s failure to address the needs of those unable or unwilling to receive a vaccine will result in a significant delay or even prevention of a return to normalcy. From here, the paper explores what a tighter marriage between healthcare and the technology sector might deliver highlighting, IntelliCentrics’ ‘trust as a technology’ as a potential solution,” continued Sheehan.

The white paper explores select topics from a pragmatic perspective posing questions such as how a free society achieves herd immunity when so many people are unwilling or unable to be vaccinated. It further considers the effect of the virus on race, ethnicity and opening international borders while recognizing any misstep puts the full burden back onto the healthcare system.

“Before the pandemic, we were accustomed to in-person visits to receive care. In a post-pandemic world, we are left searching for an alternative we can trust without sacrificing quality. IntelliCentrics ‘trust as a technology’ gives us both. By injecting trust across all healthcare interactions such as telemedicine, home-based care, visitor management, scheduling, medical staff privileging and more, IntelliCentrics is improving quality while lowering the cost for everyone,” said Sheehan.

About IntelliCentrics

With a mission to use trust to make high-quality healthcare as accessible as a good cup of coffee, IntelliCentrics created the SEC3URE Ethos. Built on three core principles – transparency, neutrality, and independence, over 11,000 locations of care worldwide rely on the SEC3URE Ethos to ensure mutual trust between patients, doctors, vendor representatives and healthcare companies. To learn more about the world’s largest trusted healthcare technology platform, visit www.intellicentrics.com. To learn more about the COVID-19 vaccine credential, visit our COVID-19 Solution Center. IntelliCentrics is publicly traded on The Stock Exchange of Hong Kong Limited under the stock code 6819.

Jennifer Xia

972-316-6523

[email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Data Management Health Technology Infectious Diseases Software General Health

MEDIA:

Logo
Logo

New Trustee Chair Announcement

UnitedAg Announces the Appointment of Glenn Miller as Chairman of the Board of Trustees

Irvine, April 05, 2021 (GLOBE NEWSWIRE) — After 16 years of service, Glenn Miller, president and chief executive officer of the Saticoy Lemon Association, is appointed Chairman of United Agricultural Benefit Trust, a leading agricultural health plan sponsored by UnitedAg.

UnitedAg, a healthcare leader for the agricultural industry, has officially announced Glenn Miller as the new in-coming Chairman for the Board of Trustees. Miller joined the Board of Trustees in 2005 and succeeds Mack Ramsay, Chairman Emeritus, who served from 2019 to 2021.

“It is a great honor to be appointed Chairman of the United Agricultural Benefit Trust. I am incredibly proud of the leadership and our accomplishments over the past four decades. Since 1983, United Agricultural Benefit Trust has provided health benefits to approximately 3 million individuals in rural communities and has paid over $830,000,000 in health, dental, vision, and life claims to plan participants and saved employers millions of dollars in premium cost. I look forward to continuing our efforts in leading the charge in providing premium health plans to an under-served community.” said Miller.

Miller has over 16 years of agricultural healthcare experience and is the current president and chief executive officer of the Saticoy Lemon Association. Representing over 170 Sunkist lemon grower members, the non-profit agricultural cooperative is responsible for marketing its grower members’ fruit through their affiliation with Sunkist Growers, Inc. The Association was established in 1933 and currently operates three processing facilities throughout Ventura County.

“This is a significant milestone for our organization. I am deeply grateful to our Board of Trustees for supporting our vision. Empathy and passion are what led to the creation of the United Agricultural Benefit Trust,” said Kirti Mutatkar, President, UnitedAg. “I am excited for what the future holds under Glenn’s leadership as he brings a wealth of non-profit agricultural experience, which is vital for the growth and development of new health programs and services.”

About UnitedAg

United Agricultural Benefit Trust, an association health plan founded in 1983 and sponsored by UnitedAg, was created to provide innovative health benefits for a strong and healthy agricultural industry. UnitedAg represents more than 1,000 agriculture-affiliated member companies and helps its members meet their employee benefits needs, promotes their interests with lawmakers, helps them comply with legislation and regulation. Based in Irvine, Calif., UnitedAg has offices in Salinas and Santa Maria and wellness centers throughout Central and Northern California.  Today, United Agricultural Benefit Trust has grown to over 220 million in annual contributions and covers more than 55,000 agricultural workers in California and Arizona. To learn more, please visit www.unitedag.org.

###

 

 

Attachment



Maribel Ochoa
UnitedAg 
949.471.3206
[email protected]

SHAREHOLDER ALERT: WeissLaw LLP Reminds CATM, KTYB, ALXN and BFTL Shareholders About Its Ongoing Investigations

PR Newswire

NEW YORK, April 5, 2021 /PRNewswire/ —


If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:


Joshua Rubin, Esq.

WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771

Kentucky Bancshares, Inc. (OTCQX: KTYB)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Kentucky Bancshares, Inc. (OTCQX: KTYB) in connection with the proposed merger of the company with Stock Yards Bancorp, Inc. (“Stock Yards”). Under the terms of the merger agreement, KTYB shareholders will receive $4.75 in cash and 0.64 shares of Stock Yards common stock for each KTYB share that they own, representing implied per-share merger consideration of approximately $37.64 based upon Stock Yards’ April 2, 2021 closing price of $51.39. If you own KTYB shares and wish to discuss this investigation or your rights, please call or visit our website: http://weisslawllp.com/ktyb/

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) in connection with the proposed acquisition of the company by AstraZeneca PLC (“AstraZeneca”). Under the terms of the agreement, ALXN shareholders will receive $60.00 and 2.1243 AstraZeneca American Depositary Shares (“ADS”) (each ADS representing one-half of one ordinary share of AstraZeneca) for each share of ALXN they hold. If you own ALXN shares and wish to discuss this investigation or your rights, please call us or visit our website:  https://weisslawllp.com/alxn/

Bank of Fincastle (OTCM: BFTL)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Bank of Fincastle (OTCM: BFTL) in connection with the proposed acquisition of the company by First National Corporation (“First National”). Under the terms of the merger agreement, BFTL shareholders may elect to receive either $3.30 in cash, 0.1649 shares of First National common stock, or a combination of cash and First National stock for each share of BFTL that they own. If you own BFTL shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:  https://www.weisslawllp.com/bftl/

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-reminds-catm-ktyb-alxn-and-bftl-shareholders-about-its-ongoing-investigations-301262436.html

SOURCE WeissLaw LLP

Endeavor Bank Announces 2020 Year End Financial Results

Endeavor Bank Announces 2020 Year End Financial Results

Loans and Deposits Exceed $281 million and $246 million, respectively, as PPP Loans Propel Growth

Assets increase 211% year over year

SAN DIEGO–(BUSINESS WIRE)–
As of December 31, 2020, the Bank’s (OTC Pink: EDVR) total assets equaled $390 million, reflecting substantial growth from December 31, 2019 of $265 million, or 211%. Total deposits equaled $246 million as of December 31, 2020, reflecting growth of $146 million or 145% from year end 2019, and total loans equaled $282 million at December 31, 2020, reflecting growth of $181 million or 179% from December 31, 2019. Between March and August of 2020, the Bank originated over 850 Paycheck Protection Program (PPP) loans totaling $175 million. At year end, total PPP loan balances equaled $118 million. The fees recognized from the origination of PPP loans significantly increased revenue, and ultimately enabled the Bank to achieve profitability.

Year End Financial Results ($000)

 

December 31, 2020

 

December 31, 2019

 

Change

Total Assets

$390,030

 

$125,421

 

$264,609 (211%)

Total Loans

$281,779

 

$100,871

 

$180,908 (179%)

Total Deposits

$246,478

 

$100,750

 

$145,728 (145%)

Total Equity

$26,843

 

$17,569

 

$9,274 (53%)1

Net Income (YTD)

$1,416

 

($3,339)

 

$4,755

1 Change in Total Equity includes net proceeds from the secondary capital offering of just under $8 million.

For the full detailed financial statements covering the Bank’s operating results, please refer to the call report filed with the FDIC at https://www7.fdic.gov/idasp/advSearchLanding.asp (Enter Endeavor Bank name and click search).

Dan Yates, CEO, stated, “Participating in the Cares Act PPP lending program was one of the seminal events in our business careers. The Federal Government chose the banking system to deliver aid to working families and we are proud to have contributed. Endeavor extended over 850 PPP loans in record time to struggling businesses to help them make payroll, saving countless jobs. Ed Carpenter of Carpenter & Company, one of the nation’s leading banking consultants, stated that Endeavor Bank ranked in the top five banks nationally for delivering PPP aid in comparison to our asset size.”

Steve Sefton, President, added, “The PPP lending program was as beneficial to bank growth and earnings as it was in supporting employment. Endeavor achieved profitable operations up to a year ahead of schedule as a result of fees earned on PPP loans.”

Sefton also noted, “In addition to achieving profitability and outperforming expectations with respect to PPP participation, another important measure of success for a bank is credit quality. So far during these challenging times, Endeavor has managed to maintain credit quality in terms of past due loans, charge offs, and any other measurement of loan quality. Endeavor’s performance to date in this area is a testament to our sound credit process and business model, which requires our bankers to maintain a close relationship with clients to better consult and assist during times of financial crisis.”

Yates further stated, “This is also a time to celebrate our success. Our growth and achievement of profitability is a tribute to our Board, our organizers, our shareholders, our professional team of highly skilled bankers, our business model, our dedication to our local business community, especially during a time of great need, but most of all, to the acceptance of our clients who have embraced and enjoyed our brand of consultative banking.”

The Board of Directors of the Bank has previously disclosed in both offering and proxy materials, that once the Bank is no longer considered a de novo institution by the appropriate regulatory authorities, it was the intention of the Board to grant nonqualified options to qualifying Bank organizers, including directors, to purchase the Bank’s common stock at an exercise price equal to the fair market value at the time of grant.

The Bank was no longer considered a de novo institution as of January 21, 2021. For this reason, in accordance with the Bank’s 2017 Equity Incentive Plan, on February 25, 2021, the Board granted 131,250 nonqualified options to certain organizers at an exercise price of $9.40 per share. The number of options granted to organizers (all of whom advanced seed capital and business assistance to start the bank) was determined by the Board in its discretion. In making that determination, the Board considered the amount of funds placed at risk by each organizer, the length of time such funds were placed at risk, and other factors deemed relevant by the Board.

About Endeavor Bank

Endeavor Bank is primarily owned and operated by San Diegans for San Diego businesses and their owners. The bank’s focus is local: local decision-making, local board, local founders, local owners, and relationships with local clients in the San Diego metropolitan marketplace and its surrounding areas.

Headquartered in downtown San Diego in the landmark Symphony Towers building, the bank also operates a loan production and executive administration office in Carlsbad. Endeavor Bank provides traditional business banking services across a broad spectrum of industries and specialties. Unique to the bank is its consultative banking approach that partners business clients with Endeavor Bank’s senior management. Together, we build strategies and provide resources that solve problems, plan for the future, and help clients’ efforts to grow revenues and profits. Visit www.bankendeavor.com for more information.

Forward-Looking Statements

This press release includes “forward-looking statements,” as such term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the current beliefs of the Bank’s directors and executive officers (collectively, “Management”), as well as assumptions made by and information currently available to the Bank’s Management. All statements regarding the Bank’s business strategy and plans and objectives of Management of the Bank for future operations, are forward-looking statements. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect” and “intend” and words or phrases of similar meaning, as they relate to the Bank or the Bank’s Management, are intended to identify forward-looking statements. Although the Bank believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Important factors that could cause actual results to differ materially from the Bank’s expectations (“cautionary statements”) are the effects of the COVID-19 pandemic and related government actions on the Bank and its customers, loan losses, changes in interest rates, loss of key personnel, lower lending limits and capital than competitors, regulatory restrictions and oversight of the Bank, the secure and effective implementation of technology, risks related to the local and national economy, the Bank’s implementation of its business plans and management of growth, loan performance, interest rates, and regulatory matters, the effects of trade, monetary and fiscal policies, inflation, and changes in accounting policies and practices. Based upon changing conditions, if any one or more of these risks or uncertainties materialize, or if any underlying assumptions prove incorrect, actual results may vary materially from those described as anticipated, believed, estimated, expected, or intended. The Bank does not intend to update these forward-looking statements.

Dan C. Yates, CEO

(858) 230-5185

[email protected]

Steven D. Sefton, President

(858) 230-4243

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Banking Small Business Professional Services

MEDIA:

Logo
Logo

NCLA Asks NJ Appellate Court to Halt Governor’s Unlawful Interference with Rental Contracts

Chuck Kravitz, et al. v. Philip D. Murphy, et al.

Washington, D.C., April 05, 2021 (GLOBE NEWSWIRE) — The New Civil Liberties Alliance, a nonpartisan, nonprofit civil rights group, filed its opening brief today in Kravitz v. Murphy in the Superior Court of New Jersey, Appellate Division. The lawsuit challenges Governor Murphy’s Executive Order No. 128 (EO 128), an unconstitutional mandate that unilaterally forces residential housing providers to use their tenants’ security deposits toward rent payments and criminalizes adherence to existing contracts. The order undermines property rights by suspending existing laws governing residential leasehold contracts and depriving property owners of security against property damage caused by tenants.

NCLA represents small property owners who have fallen victim to Governor Murphy’s unlawful order. The appellants in this case are ordinary people who are also struggling financially as a result of the pandemic. Without the contractually required security deposits, these housing providers are now forced to cover the costs of any tenant-caused property damage out of their own pockets rather than using the restitution guaranteed in the contracts they signed. In one instance, a landlord has been unable to track down former tenants who caused over $1,800 worth of damage to his rental property.

Using powers claimed under the COVID-19 public health emergency which he declared, Governor Murphy unilaterally modified the rights and obligations of housing providers and tenants who had mutually and voluntarily entered into contracts that required deposits to secure rental properties against the risk of damage. By interfering with these executed contracts that explicitly prohibited the use of security deposits to pay rent, EO 128 violates the Contracts Clause of the New Jersey Constitution.

The Governor has exceeded the emergency powers granted to him under the New Jersey Civilian Defense and Disaster Control Acts, which vest the Governor with certain enumerated authorities related to public health and the militia, having nothing to do with residential leases or security deposits. EO 128 also violates the Due Process Clause and the Separation of Powers Clause of the New Jersey Constitution. Despite the New Jersey legislature being available, Governor Murphy chose to act on his own, pursuing an approach that is neither legal nor warranted.

Governor Murphy has interfered with the contractual rights and obligations of private citizens. NCLA urges the court to restore the rule of law, on which both New Jersey housing providers and tenants depend, by declaring EO 128 unlawful.

NCLA released the following statements:

“Governor Murphy unilaterally decided that tenants were more likely than housing providers to be suffering economic hardship. So, with the single stroke of a pen, he re-wrote all the residential leases in New Jersey, depriving housing providers of the security they depend on. This order is exactly the kind of one-sided interference that the Contracts Clause forbids.”
Jared McClain, Litigation Counsel, NCLA

“It is up to the New Jersey legislature, not the Governor, to write the State’s laws. If the Governor believes that the current emergency conditions warrant a change in state law, he should ask the legislature to change the law, not attempt to make the change unilaterally.”
Richard Samp, Senior Litigation Counsel, NCLA

“It is critically important to protect both private property rights and the rule of law during times of economic and societal upheaval. Governor Murphy has admitted that he never even considered constitutional constraints when he began issuing his executive orders. EO 128 is the type of tyrannical heavy-handedness that occurs when our elected leaders ignore our constitutional framework and our individual liberties.”
Harriet Hageman, Senior Litigation Counsel, NCLA

For more information visit the case page here.

ABOUT NCLA

NCLA is a nonpartisan, nonprofit civil rights group founded by prominent legal scholar Philip Hamburger to protect constitutional freedoms from violations by the Administrative State. NCLA’s public-interest litigation and other pro bono advocacy strive to tame the unlawful power of state and federal agencies and to foster a new civil liberties movement that will help restore Americans’ fundamental rights.

###

Attachment



Judy Pino, Communications Director
New Civil Liberties Alliance
202-869-5218
[email protected]

Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin’s Lymphoma

PR Newswire

SHANGHAI and HONG KONG, April 5, 2021 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, today announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for a Phase I clinical trial to evaluate safety and tolerability of ATG-019 (monotherapy or combined with niacin ER) in patients with advanced solid tumors or non-Hodgkin’s lymphoma (NHL) in China.

As an orally bioavailable dual PAK4/NAMPT inhibitor, ATG-019 can lead to antitumor effects through energy depletion, inhibition of DNA repair, cell cycle arrest, inhibition of proliferation, and ultimately cell apoptosis. Hematological and solid tumor cells that are dependent on both PAK4 and NAMPT pathways may be susceptible to single-agent anti-tumor activity by ATG-019. ATG-019 has clear preclinical anti-tumor activity and a superior pharmacokinetics (PK) and safety profile making it an attractive novel drug candidate. Antengene has recently been conducting a Phase I clinical trial (TEACH) of ATG-019 in advanced solid tumors and NHL in Taiwan.

“The NMPA’s approval of the IND application for ATG-019 indicates the potential of this drug to be applied to Chinese patients. We look forward to initiating the first clinical trial of ATG-019 in mainland China,” said Dr. Jay Mei, Founder, Chairman and CEO of Antengene. “ATG-019 is an orally available dual PAK4/NAMPT inhibitor that achieves synergistic antitumor effects through the co-inhibition of the two pathways. We believe that ATG-019, as a novel agent under investigation, can potentially provide an additional treatment option for patients with advanced solid tumor and NHL.”

About
ATG-
019

ATG-019 is a global first-in-class oral dual PAK4/NAMPT inhibitor developed by Karyopharm Therapeutics Inc. (NASDAQ: KPTI). Antengene reached an exclusive agreement of cooperation and authorization with Karyopharm and obtained the exclusive development and commercialization rights of ATG-019 in multiple Asia-Pacific markets, including Greater China, South Korea, Australia, New Zealand and ASEAN countries.

PAK4 is a signaling protein regulating numerous fundamental cellular processes, including intracellular transport, cellular division, cell shape and motility, cell survival, immune defense and the development of cancer. PAK4 interacts with many key signaling molecules involved in cancer development such as beta-catenin, CDC42, Raf-1, BAD and myosin light chain. NAMPT is a pleiotropic protein with intra- and extra-cellular functions as an enzyme, cytokine, growth factor, and hormone that can be found in a complex with PAK4 in the cell. In preclinical mouse models, ATG-019 in combination with anti-PD-1 therapies showed improved antitumor efficacy over anti-PD-1 monotherapy, indicating the potential of the combined therapy to treat anti-PD-1 resistant patients.

Antengene is conducting a Phase I clinical trial of ATG-019 in Taiwan in patients with advanced NHL and solid tumors and are planning to conduct clinical trials exploring its combination potential with other agents.

About
Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. Antengene aims to provide the most advanced anti-cancer drugs to patients in China, the Asia Pacific Region, and around the world. Since its establishment, Antengene has built a pipeline of 12 clinical and pre-clinical stage assets and obtained 13 investigational new drug approvals in Asia Pacific. The vision of Antengene is to “Treat Patients Beyond Borders”. Antengene aims to address significant unmet medical needs by discovering, developing, and commercializing first-in-class/best-in-class therapeutics.

Forward-
looking
statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

 

Cision View original content:http://www.prnewswire.com/news-releases/antengene-announces-nmpa-approval-of-ind-application-for-atg-019-in-patients-with-advanced-solid-tumors-or-non-hodgkins-lymphoma-301262443.html

SOURCE Antengene Corporation Limited

Organigram to Report Second Quarter Fiscal 2021 Results on April 13, 2021

Organigram to Report Second Quarter Fiscal 2021 Results on April 13, 2021

MONCTON, New Brunswick–(BUSINESS WIRE)–
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its second quarter Fiscal 2021 ended February 28, 2021 on Tuesday April 13, 2021 before market open.

The Company will host a conference call to discuss the results:

Date: April 13, 2021

Time: 8:00 am Eastern Time

To register for the conference call, please use this link: http://www.directeventreg.com/registration/event/1957647

To ensure you are connected for the full call, we suggest registering a day in advance or at least 10 minutes before the start of the call. After registering, a confirmation will be sent through email, including dial in details and unique conference call codes for entry. Registration is open through the live call.

To access the webcast: https://event.on24.com/wcc/r/3079347/ADF4D345BD5DF5386FDEF631BD132518

A replay of the webcast will be available within 24 hours after the conclusion of the call at https://www.organigram.ca/investors and will be archived for a period of 90 days following the call.

About Organigram Holdings Inc.

Organigram Holdings Inc. is a NASDAQ Global Select and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.

Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Company, Indi, SHRED, Bag o’ Buds and Trailblazer. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include changes in scheduling, factors and risks as disclosed in the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR (see www.sedar.com) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

For Investor Relations enquiries, please contact:

Amy Schwalm

Vice President, Investor Relations

[email protected]

(416) 704-9057

For Media enquiries, please contact:

Marlo Taylor

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Alternative Medicine Health Other Health

MEDIA:

Logo
Logo

HitGen and BioAge Announce Research Progress in DNA-Encoded Library Based Drug Discovery Research Collaboration

HitGen and BioAge Announce Research Progress in DNA-Encoded Library Based Drug Discovery Research Collaboration

CHENGDU, China–(BUSINESS WIRE)–
Shanghai Stock Exchange listed biotech company HitGen Inc. (“HitGen”) announced important research progress in a collaboration with BioAge Labs, Inc. (“BioAge”), a private biotechnology company developing targeted small molecules for the treatment of diseases of aging. The companies have conducted collaborative research to identify and develop novel small-molecule compounds against a high-value and challenging biological target that is a critical component of the innate immune system. Dysregulation of this target is closely linked to the underlying cause of severe diseases in elderly humans, such as Alzheimer’s and cardiovascular disease.

HitGen is a world leader in the development and applications of DNA encoded library (DEL) screening. The availability of over 1 trillion small molecules generated by DEL technology and the efficiency of the screening process have made it possible for HitGen to enable drug discovery projects for many organisations around the world.

According to the terms of the collaboration agreement, HitGen has successfully applied its DEL technology and discovered program compounds that met certain criteria, and BioAge has received an exclusive license to these compounds as well as associated IP for further development and commercialization. HitGen will be eligible for milestone payments and sublicensing income from BioAge as the project progresses, in addition to research payments and an upfront license fee already paid.

“We are very pleased to collaborate with HitGen to find novel small-molecules against drug targets identified by BioAge’s platform, which analyzes samples collected over the lifespan to map the molecular pathways that drive human aging,” said Kristen Fortney, PhD, BioAge’s Chief Executive Officer. ”HitGen’s DEL technology allows BioAge to discover novel, patentable molecules that modulate key aging pathways.”

“We are enthusiastic about having the ability to identify promising hit molecules in such a short time.” said Paul Rubin, CMO and EVP Research and Development at BioAge. “These earlier-stage discovery programs will complement and accelerate our parallel in-licensing efforts, allowing us to build an extensive portfolio of clinical-stage assets that target the molecular mechanisms of aging to treat severe diseases and extend healthy human life.”

“I am delighted to see the successful identification of novel compounds for this important biological target that BioAge has been pursuing,” said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen. “This research progress is made possible by the close interaction and collaboration of the scientists from the two companies. It also reinforces the role and reputation of HitGen’s platform in the rapidly developing field of DEL and its ability to discover novel small molecules against a variety of targets. We look forward to seeing BioAge research progress further in bringing transformative medicines to patients.”

About BioAge Labs, Inc.

BioAge is a clinical-stage biotechnology company developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging. The company uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human aging. To date, BioAge has raised $127M from Andreessen Horowitz, Kaiser Foundation Hospitals, and others. In early 2021, BioAge initiated Phase 2 clinical trials of two in-licensed drugs: BGE-117, a potent inhibitor of HIF PH, is being tested for unexplained anemia of aging, and will be developed for indications related to muscle weakness; BGE-175, a PGD2 DP1 receptor inhibitor, is being tested for COVID-19, and will be developed for disorders of the aging immune system. For additional information about BioAge, visit the company’s website at www.bioagelabs.com.

About HitGen Inc.

HitGen Inc. is a rapidly developing biotech company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. It became a publicly listed company in Shanghai Stock Exchange in April 2020 (ticker code 688222.SH). HitGen has established a drug discovery research platform for small molecules and nucleic acid drugs centered on the design, synthesis, and screening of DNA encoded chemical libraries (DELs), fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) technologies. HitGen’s DELs currently contain more than 1 trillion novel, diverse, drug-like small molecules and macrocyclic compounds. These compounds are members of DELs synthesized from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and have yielded proven results for the discovery of small molecule leads against both precedented and unprecedented classes of biological targets.

Through its acquisition of Cambridge UK based Vernalis R&D Ltd, a leader in FBDD/SBDD, HitGen now has a research team of over 500 scientists and offers a full set of research capabilities including recombinant protein expression and purification, structural biology, assay development, screening, DEL synthesis, nucleic acid and small molecule chemical synthesis, computational and medicinal chemistry, biochemistry and biophysics, cell biology, in vivo pharmacology, DMPK, CMC, etc., to enable drug discovery research from target gene to IND filing.

HitGen operates a flexible business model, ranging from a single capability-based fee for services (FFS,e.g., protein expression and purification, structural biology, bioinformatics, computational chemistry, medicinal chemistry, nucleic and organic chemistry, analytical chemistry, biophysics, PK, PD, etc.), DEL screening, DEL design, synthesis and characterization, integrated drug discovery projects, risk sharing projects, collaborative ventures to program out-licensing. HitGen has approximately 20 in-house drug discovery programs at different stages of research & development. HitGen is collaborating with pharmaceutical, biotech and chemical companies, foundations and research institutes in North America, Europe, Asia, Africa, and Australia to enable the discovery and development of novel medicines and agrochemicals.

For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com.

For media inquiries: [email protected]; [email protected]

For investor inquiries: [email protected]

For business development: [email protected]

Sizhou Guo

[email protected]

KEYWORDS: China Asia Pacific

INDUSTRY KEYWORDS: Health Clinical Trials General Health Pharmaceutical Cardiology Biotechnology

MEDIA: